| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -161,774 | -147,659 |
| Cash paid for property and equipment | 142 | 115 |
| Net cash used in investing activities | -142 | -115 |
| Proceeds from issuance of common stock from exercise of stock options | 373 | 80 |
| Net proceeds from issuance of debt | 0 | 0 |
| Net proceeds from underwritten public offering | 0 | - |
| Payment of employee tax obligations related to vesting of performance stock units | -564 | - |
| Net cash (used in) provided by financing activities | -191 | 80 |
| Net decrease in cash and cash equivalents and restricted cash | -162,107 | -147,694 |
| Cash and cash equivalents at beginning of period | 300,125 | - |
| Cash and cash equivalents at end of period | 138,018 | - |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)